Skip to main content
    S

    Schrodinger Inc (SDGR)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $27.36
    -2.17 (-7.35%)

    Market Cap: $2.22B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Schrodinger Inc (SDGR) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Schrodinger (SDGR) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Schrodinger reported EPS of -$0.50, above the -$0.66 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    43%(12/28)
    Avg Surprise
    -22.24%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.26
    Range-$0.50 - -$0.05
    8 analysts
    Revenue Consensus
    $68.71M
    Range$51.74M - $78.78M
    7 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.57
    Range-$0.63 - -$0.50
    2 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.59+4.2%
    60d ago-$0.59+4.2%
    30d ago-$0.59+4.2%
    7d ago-$0.59+4.2%
    Current-$0.57
    Revenue Consensus
    $52.85M
    Range$52.10M - $53.60M
    3 analysts

    Next Report

    SDGR has an expected report date of Feb 23, 2027.

    SDGR Earnings Call

    The latest SDGR earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 28 quarters below that had an estimate, SDGR beat 12 and missed 16. Revenue for the quarter ended Sep 30, 2026 was $64.49M, up 18.7% from $54.32M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.50-$0.66-$0.81 - -$0.53+24.24%BeatN/A72 up, 3 downNov 4, 2026$64.49M
    Jun 30, 2026$0.08-$0.60N/A+113.33%BeatN/A10 up, 0 downAug 5, 2026$58.89M
    Mar 31, 2026-$0.62-$0.57-$0.59 - -$0.55-8.77%MissN/A20 up, 0 downMay 5, 2026$58.59M
    Dec 31, 2025-$0.18-$0.20N/A+7.59%BeatN/A10 up, 0 downFeb 25, 2026$87.23M
    Sep 30, 2025-$0.45-$0.75-$0.92 - -$0.52+40.00%BeatN/A90 up, 1 downNov 5, 2025$54.32M
    Jun 30, 2025-$0.65-$0.64-$0.64 - -$0.64-1.56%MissN/A11 up, 0 downAug 6, 2025$54.76M
    Mar 31, 2025-$0.64-$0.81-$0.81 - -$0.81+20.99%BeatN/A10 up, 0 downMay 7, 2025$59.55M
    Dec 31, 2024-$0.24-$0.38-$0.38 - -$0.38+36.84%BeatN/A20 up, 1 downFeb 26, 2025$88.32M
    Sep 30, 2024-$0.87-$0.63-$0.85 - -$0.06-38.10%MissN/A111 up, 0 downNov 12, 2024$35.29M
    Jun 30, 2024-$0.74-$0.89-$0.98 - -$0.71+16.85%BeatN/A90 up, 0 downJul 31, 2024$47.33M
    Mar 31, 2024-$0.76-$0.74-$0.86 - -$0.64-2.70%MissN/A80 up, 1 downMay 1, 2024$36.60M
    Dec 31, 2023-$0.41-$0.38-$0.53 - -$0.20-7.89%MissN/A70 up, 0 downFeb 28, 2024$74.13M
    Sep 30, 2023-$0.70-$0.69-$0.91 - -$0.46-1.45%MissN/A70 up, 0 downNov 1, 2023$42.57M
    Jun 30, 2023-$0.60-$0.38-$0.56 - -$0.09-57.89%MissN/A71 up, 1 downAug 2, 2023$35.19M
    Mar 31, 2023-$0.23-$0.19N/A-21.05%MissN/A51 up, 0 downMay 4, 2023$64.78M
    Dec 31, 2022-$0.38-$0.53-$0.65 - -$0.30+28.30%BeatN/A70 up, 0 downFeb 28, 2023$56.84M
    Sep 30, 2022-$0.50-$0.59-$0.82 - -$0.52+15.25%BeatN/A71 up, 0 downNov 3, 2022$36.98M
    Jun 30, 2022-$0.17-$0.49N/A+65.31%BeatN/AN/A0 up, 0 downAug 4, 2022$38.47M
    Mar 31, 2022-$0.27-$0.43-$0.60 - -$0.37+37.21%BeatN/A60 up, 0 downMay 4, 2022$48.66M
    Dec 31, 2021-$0.43-$0.39-$0.59 - -$0.01-10.26%MissN/A50 up, 0 downFeb 24, 2022$46.17M
    Sep 30, 2021-$0.38-$0.29N/A-31.03%MissN/A40 up, 0 downNov 10, 2021$29.85M
    Jun 30, 2021-$0.32-$0.09N/A-255.56%MissN/A4N/AAug 12, 2021$29.78M
    Mar 31, 2021-$0.27-$0.25-$0.29 - $0.00-8.00%MissN/A4N/AMay 11, 2021$32.13M
    Dec 31, 2020-$0.18-$0.08-$0.15 - $0.11-125.00%MissN/A4N/AMar 4, 2021$33.03M
    Sep 30, 2020-$0.22-$0.09-$0.28 - $0.04-144.44%MissN/A4N/ANov 12, 2020$25.80M
    Jun 30, 2020-$0.25-$0.32-$0.37 - -$0.14+21.88%BeatN/A4N/AAug 10, 2020$23.09M
    Mar 31, 2020-$0.22-$0.20-$0.35 - -$0.14-10.00%MissN/A4N/AMay 13, 2020$26.17M
    Dec 31, 2019-$1.11-$0.26-$0.26 - -$0.26-326.92%MissN/A1N/AMar 16, 2020$25.83M
    Sep 30, 2019-$0.01N/AN/AN/AN/AN/AN/AN/AOct 30, 2019$19.96M
    Last 29 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.92, after -$2.61 the year before. It was -$1.12 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.92N/A
    Dec 31, 2024-$2.61N/A
    Dec 31, 2023-$1.94N/A
    Dec 31, 2022-$1.32N/A
    Dec 31, 2021-$1.40N/A
    Dec 31, 2020-$0.87N/A
    Dec 31, 2019-$1.12N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,700 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,69612
    2026Q2Jun 30, 20264,07911
    2026Q1Mar 31, 20265,60213
    2025Q4Dec 31, 20257,23111
    2025Q3Sep 30, 20255,93713
    2025Q2Jun 30, 20254,91912
    2025Q1Mar 31, 20255,0439
    2024Q4Dec 31, 20247,47015

    2026Q3 Earnings Call

    Opening remarks

    Jaren Madden Chief Corporate Affairs Officer and Head of Investor Relations Thank you, and good afternoon, everyone. Welcome to today's call, during which we will provide an update on the company and review our third quarter 2026 financial results. Earlier today, we issued a press release summarizing our financial results and progress across the company, which is available on our website at schrodinger.com. During today's call, management will make statements that are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to our outlook for the full year 2026, our plans to accelerate the growth of our software business and advance our therapeutics portfolio, the capability and potential advantages of Bunsen, our Agentic AI co-scientist, the clinical potential and properties of our compounds and those of our collaborators, the use of our cash resources, as well as our future expenses. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially due to a number of important factors, including the considerations described in the Risk Factors section and elsewhere in the filings we make with the SEC, including our Form 10-Q for the quarter ended September 30, 2026. These forward-looking statements represent our views only as of today, and we caution you that, except as required by law, we may not update them in the future, whether as a result of new information, future events or otherwise. Also included in today's call are certain non-GAAP financial measures. These non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and should be considered only in addition to and not as a substitute for or superior to GAAP measures. Please refer to the tables at the end of our press release, which is available on our website, for reconciliations of these non-GAAP measures to the most directly comparable GAAP measures. This afternoon, Ramy Farid, our CEO, will review our recent progress. Then Richie Jain, Chief Financial Officer, will discuss our financial results and 2026 guidance. Karen Akinsanya, President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships, will provide an update on our therapeutics portfolio. Pat Lorton, our Chief Technology and Chief Operating Officer, will join us for the Q&A. And with that, I will turn the call over to Ramy.

    Ramy Farid CEO Thanks, Jaren, and thank you, everyone, for joining us today. Our third quarter results reflect sustained commercial momentum and strong progress toward the long-range goals we outlined earlier this year. ACV grew 17%, or 24% excluding contribution ACV.

    Frequently Asked Questions About SDGR

    When is Schrodinger's next earnings date?

    Schrodinger's next earnings report is expected for Feb 23, 2027.

    Did SDGR beat earnings estimates last quarter?

    Yes. Schrodinger reported EPS of -$0.50 for the quarter ended Sep 30, 2026, above the -$0.66 estimate, a 24.24% surprise.

    What EPS do analysts expect from SDGR next quarter?

    The consensus EPS estimate for Schrodinger for the quarter ending Dec 31, 2026 is -$0.26 from 8 analysts, with estimates from -$0.50 to -$0.05.

    How often does SDGR beat earnings estimates?

    Schrodinger beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +29.08%.